Tango Therapeutics, Inc.

NasdaqGM:TNGX Rapport sur les actions

Capitalisation boursière : US$421.1m

Tango Therapeutics Gestion

Gestion contrôle des critères 2/4

Le PDG Tango Therapeutics est Barbara Weber, nommé en Mar2017, a un mandat de 7.67 ans. La rémunération annuelle totale est $ 3.39M, composée du salaire de 18.5% et des bonus 81.5%, y compris les actions et options de la société. détient directement 1.3% des actions de la société, d'une valeur de $ 5.48M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.1 ans et 3.8 ans.

Informations clés

Barbara Weber

Directeur général

US$3.4m

Rémunération totale

Pourcentage du salaire du PDG18.5%
Durée du mandat du directeur général7.7yrs
Propriété du PDG1.3%
Durée moyenne d'occupation des postes de direction1.1yrs
Durée moyenne du mandat des membres du conseil d'administration3.8yrs

Mises à jour récentes de la gestion

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

May 30
Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Recent updates

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Oct 31
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Sep 10

What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Sep 01
What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Jun 29
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

May 30
Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Mar 19
Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Mar 06
Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

Jan 08
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

Nov 09
Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Aug 12
New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

May 10
Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer

Oct 20

Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

Oct 05
Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 13
Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M

Aug 10

We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

May 28
We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

Jan 06
We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

Analyse de la rémunération des PDG

Comment la rémunération de Barbara Weber a-t-elle évolué par rapport aux bénéfices de Tango Therapeutics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

-US$123m

Jun 30 2024n/an/a

-US$116m

Mar 31 2024n/an/a

-US$112m

Dec 31 2023US$3mUS$626k

-US$102m

Sep 30 2023n/an/a

-US$100m

Jun 30 2023n/an/a

-US$107m

Mar 31 2023n/an/a

-US$111m

Dec 31 2022US$5mUS$575k

-US$108m

Sep 30 2022n/an/a

-US$101m

Jun 30 2022n/an/a

-US$92m

Mar 31 2022n/an/a

-US$71m

Dec 31 2021US$12mUS$514k

-US$58m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$958kUS$492k

-US$52m

Rémunération vs marché: La rémunération totale de Barbara ($USD 3.39M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 2.16M ).

Rémunération et revenus: La rémunération de Barbara a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Barbara Weber (67 yo)

7.7yrs

Titularisation

US$3,391,058

Compensation

Dr. Barbara L. Weber, M.D., has been the President, Director and Chief Executive Officer of Tango Therapeutics Inc., since March 2017 and also served as Chairperson. Dr. Weber serves as a Director of OPY A...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Barbara Weber
President7.7yrsUS$3.39m1.3%
$ 5.5m
Adam Crystal
President of Research & Development1.8yrsUS$3.11m0.025%
$ 106.2k
Alan Ashworth
Founder & Member of Scientific Advisory Boardno datapas de donnéespas de données
Levi Garraway
Founderno datapas de donnéespas de données
William Kaelin
Founder & Member of Scientific Advisory Boardno datapas de donnéespas de données
Timothy Lu
Founderno datapas de donnéespas de données
Antoni Ribas
Founder & Member of Scientific Advisory Boardno datapas de donnéespas de données
Timothy Redfern
Chief Financial Officerless than a yearpas de donnéespas de données
Michael Palmieri
Head of Technical Operationsless than a yearpas de donnéespas de données
Jannik Andersen
Chief Scientific Officer1.1yrspas de donnéespas de données
Douglas Barry
Chief Legal Officer3.3yrspas de données0.041%
$ 172.4k
Julie Carretero
Chief Human Resources Officerless than a yearpas de donnéespas de données

1.1yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de TNGX n'est pas considérée comme expérimentée (ancienneté moyenne 1.1 ans), ce qui suggère une nouvelle équipe.


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Barbara Weber
President7.7yrsUS$3.39m1.3%
$ 5.5m
Alan Ashworth
Founder & Member of Scientific Advisory Board3.8yrspas de donnéespas de données
William Kaelin
Founder & Member of Scientific Advisory Board3.8yrspas de donnéespas de données
Antoni Ribas
Founder & Member of Scientific Advisory Board3.8yrspas de donnéespas de données
Alexis Borisy
Independent Chairman7.8yrsUS$171.53k0.0046%
$ 19.6k
Mace Rothenberg
Independent Director3.7yrsUS$141.53k0.023%
$ 98.0k
Kanishka Pothula
Independent Directorless than a yearpas de donnéespas de données
Lesley Calhoun
Independent Director3.7yrsUS$148.03kpas de données
Malte Peters
Independent Director6.2yrsUS$139.03k0.0046%
$ 19.6k
John Ketchum
Independent Director1.3yrsUS$375.87k0%
$ 0
Ulrich Elling
Member of Scientific Advisory Board3.8yrspas de donnéespas de données
John Doench
Member of Scientific Advisory Board3.8yrspas de donnéespas de données

3.8yrs

Durée moyenne de l'emploi

62.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de TNGX sont considérés comme expérimentés (ancienneté moyenne 3.8 ans).